Illumina (NASDAQ:ILMN) had its price target boosted by Morgan Stanley from $122.00 to $135.00 in a report released on Thursday morning. The brokerage currently has an underweight rating on the life sciences company’s stock.
A number of other research firms have also recently issued reports on ILMN. Argus increased their price objective on shares of Illumina from $205.00 to $235.00 and gave the stock a buy rating in a research report on Wednesday, September 13th. Zacks Investment Research raised shares of Illumina from a hold rating to a buy rating and set a $252.00 price target on the stock in a research report on Tuesday, December 5th. Leerink Swann reaffirmed an outperform rating and issued a $225.00 price target (up previously from $207.00) on shares of Illumina in a research report on Tuesday, September 12th. BidaskClub cut shares of Illumina from a buy rating to a hold rating in a research report on Wednesday, December 6th. Finally, Bank of America raised their price target on shares of Illumina from $215.00 to $240.00 and gave the company a buy rating in a research report on Wednesday, October 25th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the stock. Illumina currently has a consensus rating of Buy and a consensus price target of $202.60.
Illumina (ILMN) traded up $5.70 during mid-day trading on Thursday, hitting $216.55. 1,485,034 shares of the stock were exchanged, compared to its average volume of 773,021. The company has a market cap of $31,616.30, a PE ratio of 63.32, a PEG ratio of 3.57 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. Illumina has a one year low of $126.18 and a one year high of $230.72.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The company had revenue of $714.00 million for the quarter, compared to analysts’ expectations of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business’s revenue was up 17.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.97 EPS. research analysts forecast that Illumina will post 3.75 EPS for the current year.
In other news, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $202.23, for a total transaction of $29,323.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $203.27, for a total transaction of $4,065,400.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 136,421 shares of company stock valued at $28,489,101. 0.89% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of ILMN. Winslow Capital Management LLC purchased a new stake in shares of Illumina during the 2nd quarter worth approximately $211,584,000. HPM Partners LLC grew its stake in Illumina by 29,103.8% in the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after buying an additional 749,424 shares in the last quarter. Fred Alger Management Inc. grew its stake in Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after buying an additional 548,030 shares in the last quarter. TIAA CREF Investment Management LLC grew its stake in Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after buying an additional 527,548 shares in the last quarter. Finally, Capital World Investors grew its stake in Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares in the last quarter. Institutional investors own 91.75% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/12/17/illumina-ilmn-price-target-raised-to-135-00.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.